Glenmark Gets Approval For Favipiravir As COVID-19 Treatment

Credit: pixabay.com

In the midst of the fight against the Corona virus, the drug of Glenmark Pharmaceuticals will now be used to treat Corona patients. Glenmark Pharmaceuticals has also received its government approval. Patients with mild symptoms of corona can now be given medication from Glenmark Pharmaceuticals.

The Mumbai-based company said the approval was part of India’s accelerated approval process and the drug was meant for “restricted emergency use,” meaning patients must sign their consent before being treated by the drug.

Favipiravir is also undergoing trials in other countries to test its efficacy as a COVID-19 treatment.

Japan’s Fujifilm Holdings Corp, which makes favipiravir under the brand name Avigan, said last week its research on the drug as a potential COVID-19 treatment may drag on until July.

Drug firm Glenmark Pharmaceuticals on Saturday said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate Covid-19 at a price of about Rs 103 per tablet.

The drug will be available as a 200 mg tablet at a maximum retail price (MRP) of Rs 3,500 for a strip of 34 tablets, Glenmark Pharmaceuticals said.

Current Issue

NEWSLETTER